These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1939964)

  • 21. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
    J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
    Collen D
    Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study of new thrombolytic agents in myocardial infarction: a multicenter randomized trial (APSAC versus rt-PA)].
    Cassagnes J; Machecourt J; Bassand JP; Lusson JR; Wolf JE; Anguenot T; Maublant J; Fagret D; Cardot JC
    Arch Mal Coeur Vaiss; 1992 Nov; 85(11):1593-9. PubMed ID: 1300957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
    Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J
    Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current issues concerning thrombolytic therapy for acute myocardial infarction.
    Hennekens CH; O'Donnell CJ; Ridker PM; Marder VJ
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):18S-22S. PubMed ID: 7775709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Thrombolytic therapy].
    de Gaetano G; Donati MB; Gensini GF; Restagno C
    Recenti Prog Med; 1993 Sep; 84(9):581-5. PubMed ID: 8210621
    [No Abstract]   [Full Text] [Related]  

  • 27. Thrombolysis in acute myocardial infarction.
    Holmberg SR
    Br J Hosp Med; 1992 Apr 15-May 5; 47(8):572-6, 578-80. PubMed ID: 1591557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombolytic therapy in Europe: current status.
    Vahanian A
    Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. The TEAM-3 investigators.
    Karagounis LA; Anderson JL; Sorensen SG; Moreno FL
    Am J Cardiol; 1994 Jan; 73(1):16-22. PubMed ID: 8279371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
    Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
    J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myocardial infarction, thrombolytic therapy, and economics.
    Conti RC
    Clin Cardiol; 1993 Sep; 16(9):635. PubMed ID: 8242906
    [No Abstract]   [Full Text] [Related]  

  • 33. Which thrombolytic agent should one choose?
    Topol EJ
    Prog Cardiovasc Dis; 1991; 34(3):165-78. PubMed ID: 1947122
    [No Abstract]   [Full Text] [Related]  

  • 34. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fibrinolytic agents--who benefits when?].
    Weichert W; Seifried E
    Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS; Avins AL
    Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC
    Internist (Berl); 1992 May; 33(5):364-5. PubMed ID: 1612871
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study.
    Munkvad S; Jespersen J; Gram J; Kluft C
    J Am Coll Cardiol; 1991 Mar; 17(4):957-62. PubMed ID: 1900313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.